Could a 5-Day drug course make surgery safer for liver patients with low platelets?

NCT ID NCT06642740

Completed Disease control Sponsor: Beijing Ditan Hospital Source: ClinicalTrials.gov ↗

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This study tests whether a 5-day course of avatricopal can safely raise platelet counts in people with chronic liver disease who have low platelets and need surgery. The goal is to see if more patients reach a platelet count of at least 50×10⁹/L on the day of their procedure, which could lower bleeding risks. Researchers will also monitor for side effects like blood clots or bleeding events.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: a drug called avatricopal
What this could lead to: If it works, avatricopal could offer a way to safely increase platelet counts before surgery in people with chronic liver disease, reducing the need for platelet transfusions.
What could go wrong: This is a relatively small, early-stage study, so results may not apply broadly. The drug could cause side effects like thrombotic events, and its long-term safety is not yet known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LIVER DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

liver disorder thrombocytopenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC LIVER DISEASE THROMBOPENIA

Contacts and locations

Show contact details

Locations

Beijing Ditan Hospital,Capital Medical University

Beijing, Beijing Municipality, 100015, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.